Abstract
Pharmacologic intervention for the failing heart has traditionally targeted neurohormonal activation and ventricular remodeling associated with cardiac dysfunction. Despite the multitude of agents available for the treatment of heart failure, it remains a highly prevalent clinical syndrome with substantial morbidity and mortality, necessitating alternative strategies of targeted management. One such area of interest is the ability to modulate myocardial glucose uptake and its impact on cardioprotection. Glucose‐insulin‐potassium (GIK) infusions have been studied for decades, with conflicting results regarding benefit in acute myocardial infarction. Based on the same concepts, glucagon‐like peptide‐1‐[7–36] amide (GLP‐1) has recently been demonstrated to be a more effective alternative in left ventricular (LV) systolic dysfunction. This paper provides a review on the current evidence supporting the use of GLP‐1 in both animal models and humans with ischemic and nonischemic cardiomyopathy. Copyright © 2009 Wiley Periodicals, Inc.
Full Text
The Full Text of this article is available as a PDF (1.4 MB).
References
- 1. Neubauer S. The failing heart–an engine out of fuel. N Engl J Med 2007; 356: 1140–1151. [DOI] [PubMed] [Google Scholar]
- 2. Stanley AW, Jr. , Moraski RE, Russell RO, Rogers WJ, Mantle JA, et al. Effects of glucose‐insulin‐potassium on myocardial substrate availability and utilization in stable coronary artery disease. Studies on myocardial carbohydrate, lipid and oxygen arterial‐coronary sinus differences in patients with coronary artery disease. Am J Cardiol 1975; 36: 929–937. [DOI] [PubMed] [Google Scholar]
- 3. Apstein CS. The benefits of glucose‐insulin‐potassium for acute myocardial infarction (and some concerns). J Am Coll Cardiol 2003; 42: 792–795. [DOI] [PubMed] [Google Scholar]
- 4. Diaz R, Paolasso EA, Piegas LS, Tajer CD, Moreno MG, et al. Metabolic modulation of acute myocardial infarction. The ECLA (Estudios Cardiológicos Latinoamérica) Collaborative Group. Circulation 1998; 98: 2227–2234. [DOI] [PubMed] [Google Scholar]
- 5. van der Horst IC, Zijlstra F, van't Hof AW, Doggen CJ, de Boer MJ, et al; Zwolle Infarct Study Group. Glucose‐insulin‐potassium infusion inpatients treated with primary angioplasty for acute myocardial infarction: the glucose‐insulin‐potassium study: a randomized trial. J Am Coll Cardiol 2003; 42: 784–791. [DOI] [PubMed] [Google Scholar]
- 6. Mehta SR, Yusuf S, Diaz R, Zhu J, Pais P, et al; CREATE‐ECLA Trial Group Investigators. Effect of glucose‐insulin‐potassium infusion on mortality in patients with acute ST‐segment elevation myocardial infarction: the CREATE‐ECLA randomized controlled trial. JAMA 2005; 293: 437–446. [DOI] [PubMed] [Google Scholar]
- 7. Rasoul S, Ottervanger JP, Timmer JR, Svilaas T, Henriques JP, et al. One year outcomes after glucose‐insulin‐potassium in ST elevation myocardial infarction. The Glucose‐insulin‐potassium study II. Int J Cardiol 2007; 122: 52–55. [DOI] [PubMed] [Google Scholar]
- 8. Intensive blood‐glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 837–853. [PubMed] [Google Scholar]
- 9. Effect of intensive blood‐glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 854–865. [PubMed] [Google Scholar]
- 10. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 2457–2471. [DOI] [PubMed] [Google Scholar]
- 11. Baggio LL, Drucker DJ, Harnessing the therapeutic potential of glucagon‐like peptide‐1: a critical review. Treat Endocrinol 2002; 1: 117–125. [DOI] [PubMed] [Google Scholar]
- 12. Todd JF, Wilding JP, Edwards CM, Khan FA, Ghatei MA, Bloom SR. Glucagon‐like peptide‐1 (GLP‐1): a trial of treatment in non‐insulin‐dependent diabetes mellitus. Eur J Clin Invest 1997; 27: 533–536. [DOI] [PubMed] [Google Scholar]
- 13. Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6‐week course of glucagon‐like peptide 1 on glycaemic control, insulin sensitivity, and beta‐cell function in type 2 diabetes: a parallel‐group study. Lancet 2002; 359: 824–830. [DOI] [PubMed] [Google Scholar]
- 14. Nikolaidis LA, Doverspike A, Hentosz T, Zourelias L, Shen YT, et al. Glucagon‐like peptide‐1 limits myocardial stunning following brief coronary occlusion and reperfusion in conscious canines. J Pharmacol Exp Ther 2005; 312: 303–308. [DOI] [PubMed] [Google Scholar]
- 15. Zhao T, Parikh P, Bhashyam S, Bolukoglu H, Poornima I, et al. Direct effects of glucagon‐like peptide‐1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts. J Pharmacol Exp Ther 2006; 317: 1106–1113. [DOI] [PubMed] [Google Scholar]
- 16. Bose AK, Mocanu MM, Carr RD, Brand CL, Yellon DM. Glucagon‐like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes 2005; 54: 146–151. [DOI] [PubMed] [Google Scholar]
- 17. Nikolaidis LA, Elahi D, Hentosz T, Doverspike A, Huerbin R, et al. Recombinant glucagon‐like peptide‐1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing‐induced dilated cardiomyopathy. Circulation 2004; 110: 955–961. [DOI] [PubMed] [Google Scholar]
- 18. Nikolaidis LA, Mankad S, Sokos GG, Miske G, Shah A, et al. Effects of glucagon‐like peptide‐1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 2004; 109: 962–965. [DOI] [PubMed] [Google Scholar]
- 19. Sokos GG, Nikolaidis LA, Mankad S, Elahi D, Shannon RP. Glucagon‐like peptide‐1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail 2006; 12: 694–699. [DOI] [PubMed] [Google Scholar]
- 20. Sokos GG, Bolukoglu H, German J, Hentosz T, Magovern GJ Jr, et al. Effect of glucagon‐like peptide‐1 (GLP‐1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting. Am J Cardiol 2007; 100: 824–829. [DOI] [PubMed] [Google Scholar]